Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06045806 | A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation(KarMMa-9) | active not recruiting | Phase 3 | 79 | CelgeneINDUSTRY | 18 | Mar 5, 2026 | clinicaltrials |
| NCT02659293 | Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | active not recruiting | Phase 3 | 180 | University of Chicago |
| 2 |
| Mar 4, 2026 |
| clinicaltrials |
| NCT03729804 | Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)((COBRA)) | active not recruiting | Phase 3 | 250 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05316701 | Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies(Orca-T) | active not recruiting | Phase 3 | 187 | Orca Biosystems, Inc.INDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03710603 | Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma(Perseus) | active not recruiting | Phase 3 | 709 | Stichting European Myeloma NetworkNETWORK | 13 | Feb 10, 2026 | clinicaltrials |
| NCT04751877 | Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). | active not recruiting | Phase 3 | 270 | Poitiers University HospitalOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06097364 | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma(OLYMPIA-2) | active not recruiting | Phase 3 | 733 | Regeneron PharmaceuticalsINDUSTRY | 17 | Feb 6, 2026 | clinicaltrials |
| NCT00572169 | UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy | active not recruiting | Phase 3 | 177 | University of ArkansasOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03617731 | Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) | active not recruiting | Phase 3 | 662 | University of Heidelberg Medical CenterOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04965493 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)(BRUIN CLL-322) | active not recruiting | Phase 3 | 600 | Loxo Oncology, Inc.INDUSTRY | 23 | Jan 29, 2026 | clinicaltrials |
| NCT01208662 | Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65(DFCI 10-106) | active not recruiting | Phase 3 | 729 | Paul Richardson, MDOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04270409 | Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma | active not recruiting | Phase 3 | 337 | SanofiINDUSTRY | 24 | Dec 12, 2025 | clinicaltrials |
| NCT05028348 | A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma | active not recruiting | Phase 3 | 117 | European Myeloma Network B.V.NETWORK | 4 | Dec 4, 2025 | clinicaltrials |
| NCT04459416 | Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma | active not recruiting | Phase 3 | 299 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05371093 | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma(ZUMA-22) | active not recruiting | Phase 3 | 231 | Kite, A Gilead CompanyINDUSTRY | 7 | Oct 15, 2025 | clinicaltrials |
| NCT03057054 | Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 3 | 173 | Children's Oncology GroupNETWORK | 2 | Oct 6, 2025 | clinicaltrials |
| NCT05556720 | Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial(BOOST-IC) | active not recruiting | Phase 3 | 960 | Monash UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT02716233 | A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents(CAALL-F01) | active not recruiting | Phase 3 | 2,044 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT01863550 | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 3 | 1,087 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 8, 2025 | clinicaltrials |
| NCT00002462 | RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease | active not recruiting | Phase 3 | 615 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Aug 5, 2025 | clinicaltrials |
| NCT00005584 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | active not recruiting | Phase 3 | 1,649 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Aug 5, 2025 | clinicaltrials |
| NCT00379041 | Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma | active not recruiting | Phase 3 | 1,158 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Aug 5, 2025 | clinicaltrials |
| NCT04851717 | Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures | active not recruiting | Phase 2 / Phase 3 | 100 | Acacia Pharma LtdINDUSTRY | 2 | Jul 1, 2025 | clinicaltrials |
| NCT04668690 | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL | active not recruiting | Phase 3 | 193 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | May 31, 2025 | clinicaltrials |
| NCT04722848 | Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | active not recruiting | Phase 3 | 236 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT03836261 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL(AMPLIFY) | active not recruiting | Phase 3 | 984 | Acerta Pharma BVINDUSTRY | 27 | Dec 27, 2024 | clinicaltrials |
| NCT03836014 | Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma(CONFIRM) | active not recruiting | Phase 3 | 436 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT04934475 | MInimal Residual Disease Adapted Strategy(MIDAS) | active not recruiting | Phase 3 | 791 | Intergroupe Francophone du MyelomeNETWORK | 3 | Nov 7, 2024 | clinicaltrials |
| NCT06475820 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis | active not recruiting | Phase 2 / Phase 3 | 150 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT00943423 | PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma(RAPID) | active not recruiting | Phase 3 | 602 | University College, LondonOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT05515029 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | active not recruiting | Phase 3 | 56 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03948035 | Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | active not recruiting | Phase 3 | 576 | Wuerzburg University HospitalOTHER | 2 | May 6, 2023 | clinicaltrials |
| NCT02544308 | Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma(IDRIS) | active not recruiting | Phase 3 | 36 | University College, LondonOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT03742297 | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | active not recruiting | Phase 3 | 462 | PETHEMA FoundationOTHER | 1 | Sep 14, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 5, 2026source: clinicaltrials